* Says drug shows no difference in disease response
* Drug studied in patients with advanced multiple myeloma
June 9 (Reuters) - Human Genome Sciences Inc HGSI.O said data from a mid-stage trial of its experimental cancer drug showed the drug did not improve progression-free survival or disease response.
The drug, mapatumumab, was studied in combination with bortezomib in patients with advanced multiple myeloma, the company said in a statement.
Multiple myeloma results from abnormal plasma cells, usually in the bone marrow.
The company said the drug was well tolerated in the study, and said it expects to present full details at a scientific meeting later in the year.
Shares of the company closed at $23.67 Tuesday on Nasdaq. (Reporting by Shailesh Kuber in Bangalore; Editing by Vyas Mohan)